Citadel Advisors
DTIL icon

Citadel Advisors’s Precision BioSciences DTIL Stock Holding History

Citadel Advisors’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-150
Closed -$1.64K – 14716
2023
Q4 		$1.64K Sell
150
-47
-24% -$507 ﹤0.01% 13795
2023
Q3 		$2.01K Sell
197
-113
-36% -$1.74K ﹤0.01% 13771
2023
Q2 		$4.89K Sell
310
-40
-11% -$915 ﹤0.01% 13554
2023
Q1 		$7.91K Sell
350
-50
-13% -$1.65K ﹤0.01% 13691
2022
Q4 		$14.3K Sell
400
-120
-23% -$4.74K ﹤0.01% 13402
2022
Q3 		$20K Buy
+520
New +$24.7K ﹤0.01% 12071
2021
Q4 		– Sell
-1,330
Closed -$460K – 13971
2021
Q3 		$460K Sell
1,330
-200
-13% -$67.8K ﹤0.01% 10078
2021
Q2 		$575K Buy
1,530
+883
+136% +$265K ﹤0.01% 9738
2021
Q1 		$201K Sell
647
-113
-15% -$39.6K ﹤0.01% 11690
2020
Q4 		$190K Sell
760
-140
-16% -$34.3K ﹤0.01% 9775
2020
Q3 		$166K Buy
900
+130
+17% +$25.9K ﹤0.01% 8945
2020
Q2 		$192K Buy
770
+143
+23% +$31.3K ﹤0.01% 8560
2020
Q1 		$113K Sell
627
-36
-5% -$9.42K ﹤0.01% 8547
2019
Q4 		$276K Buy
+663
New +$208K ﹤0.01% 7714

Other funds holding DTIL

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Citadel Advisors's DTIL Position: Q2 2026 in Review

Citadel Advisors reduced its Precision BioSciences (DTIL) stake by 41% in Q2 2026, selling an estimated $334K and leaving 68,552 shares worth $539K. The position accounts for ﹤0.01% of the portfolio, ranked #9677.

Citadel Advisors first reported a position in DTIL in Q1 2019 and has held it in 28 quarters since. The position peaked at $12.6M in Q4 2020. 95 funds tracked by Wall St. Rank hold DTIL as of Q2 2026.

  • Citadel Advisors held 68,552 shares of Precision BioSciences worth $539K as of Q2 2026.
  • Citadel Advisors sold 47,400 Precision BioSciences shares in Q2 2026, an estimated $334K.
  • Precision BioSciences made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #9677 holding.
  • Citadel Advisors first reported a position in Precision BioSciences in Q1 2019 and has held it in 28 quarters since.
  • Citadel Advisors's Precision BioSciences position peaked at $12.6M in Q4 2020.
  • 95 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.